Download PDF
Clin Colon Rectal Surg 2016; 29(03): 232-238
DOI: 10.1055/s-0036-1584292
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms

Chelsie K. Sievers
1   Department of Oncology, University of Wisconsin, Madison, Wisconsin
2   Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin, Madison, Wisconsin
,
Jeremy D. Kratz
3   Division of Hematology and Oncology, Department of Medicine, University of Wisconsin, Madison, Wisconsin
,
Luke D. Zurbriggen
3   Division of Hematology and Oncology, Department of Medicine, University of Wisconsin, Madison, Wisconsin
,
Noelle K. LoConte
3   Division of Hematology and Oncology, Department of Medicine, University of Wisconsin, Madison, Wisconsin
4   University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin
,
Sam J. Lubner
3   Division of Hematology and Oncology, Department of Medicine, University of Wisconsin, Madison, Wisconsin
4   University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin
,
Natalya Uboha
3   Division of Hematology and Oncology, Department of Medicine, University of Wisconsin, Madison, Wisconsin
4   University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin
,
Daniel Mulkerin
3   Division of Hematology and Oncology, Department of Medicine, University of Wisconsin, Madison, Wisconsin
4   University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin
,
Kristina A. Matkowskyj
1   Department of Oncology, University of Wisconsin, Madison, Wisconsin
4   University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin
5   William S Middleton Memorial Veterans Hospital, Madison, Wisconsin
6   Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin
,
Dustin A. Deming
3   Division of Hematology and Oncology, Department of Medicine, University of Wisconsin, Madison, Wisconsin
4   University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin
5   William S Middleton Memorial Veterans Hospital, Madison, Wisconsin
› Author Affiliations
Further Information

Publication History

Publication Date:
19 August 2016 (online)

    Permissions and Reprints

Abstract

As treatment strategies for patients with colorectal cancer advance, there has now become an ever-increasing need for multidisciplinary teams to care for these patients. Recent investigations into the timing and duration of perioperative therapy, as well as, the rise of molecular profiling have led to more systemic chemotherapeutic options. The most efficacious use, in terms of timing and patient selection, of these therapies in the setting of modern operative and radiotherapy techniques requires the generation of care teams discussing cases at multidisciplinary conferences. This review highlights the role of multidisciplinary team conferences, advances in perioperative chemotherapy, current clinical biomarkers, and emerging therapeutic agents for molecular subtypes of metastatic colon cancer. As our understanding of relevant molecular subtypes increases and as data becomes available on treatment response, the treatment of colorectal cancer will become more precise and effective.

Keywords

colon cancer - rectal cancer - chemotherapy
 

  • References

  • 1 American Cancer Society. Cancer Facts & Figures 2016. Atlanta, GA: American Cancer Society; 2016
    Google Scholar
  • 2 Glimelius B, Dahl O, Cedermark B , et al; Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic gastrointestinal tumour adjuvant therapy group. Acta Oncol 2005; 44 (8) 904-912
    CrossrefPubMedGoogle Scholar
  • 3 Fuchs CS, Marshall J, Mitchell E , et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25 (30) 4779-4786
    CrossrefPubMedGoogle Scholar
  • 4 de Gramont A, Figer A, Seymour M , et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18 (16) 2938-2947
    CrossrefPubMedGoogle Scholar
  • 5 Venook AP, Niedzwiecki D, Lenz HJ , et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum. J Clin Oncol 2014; (Supplemental Abstract LBA3)
    PubMedGoogle Scholar
  • 6 Nordlinger B, Sorbye H, Glimelius B , et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371 (9617) 1007-1016
    CrossrefPubMedGoogle Scholar
  • 7 National Institute for Health and Care Excellence. Improving outcomes in colorectal cancer. NICE guidelines [CSG5] Published date: June 2004. Available at: https://www.nice.org.uk/guidance/CSG5 . Accessed August 27, 2015
    PubMedGoogle Scholar
  • 8 Burton S, Brown G, Daniels IR, Norman AR, Mason B, Cunningham D ; Royal Marsden Hospital, Colorectal Cancer Network. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?. Br J Cancer 2006; 94 (3) 351-357
    CrossrefPubMedGoogle Scholar
  • 9 Snelgrove RC, Subendran J, Jhaveri K , et al. Effect of Multidisciplinary Cancer Conference on Treatment Plan for Patients With Primary Rectal Cancer. Dis Colon Rectum 2015; 58 (7) 653-658
    CrossrefPubMedGoogle Scholar
  • 10 MacDermid E, Hooton G, MacDonald M , et al. Improving patient survival with the colorectal cancer multi-disciplinary team. Colorectal Dis 2009; 11 (3) 291-295
    CrossrefPubMedGoogle Scholar
  • 11 Taylor C, Finnegan-John J, Green JSA. “No decision about me without me” in the context of cancer multidisciplinary team meetings: a qualitative interview study. BMC Health Serv Res 2014; 14: 488
    PubMedGoogle Scholar
  • 12 Des Guetz G, Uzzan B, Morere J-F, Perret G, Nicolas P. Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. Cochrane Database Syst Rev 2010; (1) CD007046
    PubMedGoogle Scholar
  • 13 Saini A, Norman AR, Cunningham D , et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003; 88 (12) 1859-1865
    CrossrefPubMedGoogle Scholar
  • 14 André T, Iveson T, Labianca R , et al; for the IDEA Steering Committee. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep 2013; 9: 261-269
    CrossrefPubMedGoogle Scholar
  • 15 André T, Boni C, Mounedji-Boudiaf L , et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350 (23) 2343-2351
    CrossrefPubMedGoogle Scholar
  • 16 André T, Boni C, Navarro M , et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27 (19) 3109-3116
    CrossrefPubMedGoogle Scholar
  • 17 Van Cutsem E, Labianca R, Bodoky G , et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27 (19) 3117-3125
    CrossrefPubMedGoogle Scholar
  • 18 Taieb J, Tabernero J, Mini E , et al; PETACC-8 Study Investigators. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15 (8) 862-873
    CrossrefPubMedGoogle Scholar
  • 19 de Gramont A, Van Cutsem E, Schmoll H-J , et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13 (12) 1225-1233
    CrossrefPubMedGoogle Scholar
  • 20 Loupakis F, Cremolini C, Masi G , et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371 (17) 1609-1618
    CrossrefPubMedGoogle Scholar
  • 21 Bayraktar UD, Chen E, Bayraktar S , et al. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?. Cancer 2011; 117 (11) 2364-2370
    CrossrefPubMedGoogle Scholar
  • 22 Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012; 13 (11) 1152-1160
    CrossrefPubMedGoogle Scholar
  • 23 Lièvre A, Bachet J-B, Le Corre D , et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66 (8) 3992-3995
    CrossrefPubMedGoogle Scholar
  • 24 Lièvre A, Bachet J-B, Boige V , et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26 (3) 374-379
    CrossrefPubMedGoogle Scholar
  • 25 Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F , et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67 (6) 2643-2648
    CrossrefPubMedGoogle Scholar
  • 26 Di Fiore F, Blanchard F, Charbonnier F , et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96 (8) 1166-1169
    CrossrefPubMedGoogle Scholar
  • 27 Van Cutsem E, Vervenne WL, Bennouna J , et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27 (13) 2231-2237
    CrossrefPubMedGoogle Scholar
  • 28 De Roock W, Claes B, Bernasconi D , et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11 (8) 753-762
    CrossrefPubMedGoogle Scholar
  • 29 Bokemeyer C, Bondarenko I, Hartmann JT , et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22 (7) 1535-1546
    CrossrefPubMedGoogle Scholar
  • 30 Douillard J-Y, Oliner KS, Siena S , et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369 (11) 1023-1034
    CrossrefPubMedGoogle Scholar
  • 31 Allegra CJ, Jessup JM, Somerfield MR , et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27 (12) 2091-2096
    CrossrefPubMedGoogle Scholar
  • 32 Tejpar S, Lenz H-J, Koehne C-H , et al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. J Clin Oncol 2014; 32 (Suppl 31:LBA444)
    PubMedGoogle Scholar
  • 33 Van Cutsem E, Lenz H-J, Köhne C-H , et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33 (7) 692-700
    CrossrefPubMedGoogle Scholar
  • 34 Peeters M, Siena S, Tabernero J , et al. Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS). J Clin Oncol 2014; 33: 5S (Supplemental Abstract 3557)
    PubMedGoogle Scholar
  • 35 Davies H, Bignell GR, Cox C , et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417 (6892) 949-954
    CrossrefPubMedGoogle Scholar
  • 36 Samowitz WS, Sweeney C, Herrick J , et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65 (14) 6063-6069
    CrossrefPubMedGoogle Scholar
  • 37 Di Nicolantonio F, Martini M, Molinari F , et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26 (35) 5705-5712
    CrossrefPubMedGoogle Scholar
  • 38 Laurent-Puig P, Cayre A, Manceau G , et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27 (35) 5924-5930
    CrossrefPubMedGoogle Scholar
  • 39 Richman SD, Seymour MT, Chambers P , et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27 (35) 5931-5937
    CrossrefPubMedGoogle Scholar
  • 40 Bokemeyer C, Van Cutsem E, Rougier P , et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48 (10) 1466-1475
    CrossrefPubMedGoogle Scholar
  • 41 Peeters M, Price TJ, Cervantes A , et al. 546P Tumour Shrinkage And Response Outcomes During Second-Line Panitumumab (PMAB)+ Folfiri VS Folfiri Treatment. Ann Oncol 2014; 25 (Suppl. 04) iv167-iv209.10.1093/annonc/mdu33
    PubMedGoogle Scholar
  • 42 Barault L, Veyrie N, Jooste V , et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008; 122 (10) 2255-2259
    CrossrefPubMedGoogle Scholar
  • 43 Prenen H, De Schutter J, Jacobs B , et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15 (9) 3184-3188
    CrossrefPubMedGoogle Scholar
  • 44 Sartore-Bianchi A, Martini M, Molinari F , et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69 (5) 1851-1857
    CrossrefPubMedGoogle Scholar
  • 45 Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3 (10) 1221-1224
    CrossrefPubMedGoogle Scholar
  • 46 Sood A, McClain D, Maitra R , et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 2012; 11 (2) 143-150
    CrossrefPubMedGoogle Scholar
  • 47 Network CGA ; Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487 (7407) 330-337
    CrossrefPubMedGoogle Scholar
  • 48 Bertotti A, Migliardi G, Galimi F , et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1 (6) 508-523
    CrossrefPubMedGoogle Scholar
  • 49 Frank D, Jumonville A, Loconte NK , et al. A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study. J Gastrointest Oncol 2012; 3 (2) 90-96
    PubMedGoogle Scholar
  • 50 Deeken JF, Wang H, Marshall J , et al. Final results of a phase I study of lapatinib (LAP) and cetuximab (CET) in patients with CET-sensitive solid tumors. J CLin Oncol 2013; 31: 15 (Supplemental Abstract 2616)
    CrossrefPubMedGoogle Scholar
  • 51 Rubinson DA, Hochster HS, Ryan DP , et al. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs 2014; 32 (1) 113-122
    CrossrefPubMedGoogle Scholar
  • 52 Siena S, Sartore-Bianchi A, Lonardi S , et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol 2015; 33: 15 (Supplemental Abstract 3508)
    PubMedGoogle Scholar
  • 53 Corcoran RB, Ebi H, Turke AB , et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2 (3) 227-235
    CrossrefPubMedGoogle Scholar
  • 54 Hong DS, Morris VK, El Osta BE , et al. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 2015; 33: 15 (Supplemental Abstract 3511)
    PubMedGoogle Scholar
  • 55 Benatti P, Gafà R, Barana D , et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005; 11 (23) 8332-8340
    CrossrefPubMedGoogle Scholar
  • 56 Funkhouser Jr WK, Lubin IM, Monzon FA , et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn 2012; 14 (2) 91-103
    CrossrefPubMedGoogle Scholar
  • 57 Bonis PA, Trikalinos TA, Chung M , et al. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep) 2007; (150) 1-180
    PubMedGoogle Scholar
  • 58 Topalian SL, Hodi FS, Brahmer JR , et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366 (26) 2443-2454
    CrossrefPubMedGoogle Scholar
  • 59 Brahmer JR, Drake CG, Wollner I , et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28 (19) 3167-3175
    CrossrefPubMedGoogle Scholar
  • 60 Le DT, Uram JN, Wang H , et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26) 2509-2520
    CrossrefPubMedGoogle Scholar